New hope for painful skin condition: experimental drug LAD191 enters mid-stage trial

NCT ID NCT07151937

Recruiting now Disease control Sponsor: Almirall, S.A. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This study tests a new drug, LAD191, in 200 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition that causes boils and tunnels under the skin. The goal is to see if LAD191 can reduce the number of inflamed lesions better than a placebo. Participants will receive either LAD191, a placebo, or an active comparator, and results will be measured by how many achieve at least a 50% reduction in lesions without worsening abscesses or draining tunnels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital de Manises
RECRUITING

Manises, 46940, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HIDRADENITIS SUPPURATIVA